Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · December 21, 2023

Outcomes of 3-Week vs 4-Week Schedule of Nab-Paclitaxel Therapy in Patients With Metastatic Breast Cancer

The Oncologist


Additional Info

The Oncologist
Three-Week Versus 4-Week Schedule of nab-Paclitaxel in Patients With Metastatic Breast Cancer: A Randomized Phase II Study
Oncologist 2023 Dec 11;28(12)1102-e1302, Y Liu, G Song, L Di, H Jiang, R Ran, R Zhang, Y Zhang, H Li

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading